Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.
a Department of Hematology , Roskilde University Hospital , Roskilde , Denmark.|b Institute for Inflammation Research, Department of Rheumatology , Copenhagen University Hospital , Rigshospitalet, Copenhagen , Denmark.
Mads Emil
ME
Bjørn
a Department of Hematology , Roskilde University Hospital , Roskilde , Denmark.
Morten Orebo
MO
Holmström
a Department of Hematology , Roskilde University Hospital , Roskilde , Denmark.
Hans Carl
HC
Hasselbalch
D000368:Aged; D000369:Aged, 80 and over; D001792:Blood Platelets; D003718:Denmark; D019468:Disease Management; D005260:Female; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009570:Nitriles; D010976:Platelet Count; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome
D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases
Bleeding; JAK2V617F; myelofibrosis; ruxolitinib; thrombocytopenia